NCT01436162已完成3 期
The SPD489-323 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Shire
- 入组人数
- 1,105
- 试验地点
- 101
- 主要终点
- Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 8 Weeks
研究概览
简要总结
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. Eligible patients will remain on their antidepressant but will be randomized to either receive supplemental SPD489 or placebo (i.e. sugar pill). The purpose of this study is to help answer the following questions:
- How safe is SPD489 for the supplemental treatment of depression and what are the side effects that might be related to it?
- Can supplemental SPD489 help patients who still have residual depression symptoms while taking an antidepressant?
- How much SPD489 should be given to patients with depression who are also taking an antidepressant?
- How does SPD489 compare to placebo in depressed patients who are also taking an antidepressant?
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •Subject whose current episode of MDD has not responded to an adequate treatment regimen with 2 or more approved single antidepressant agents.
- •Subject who has a lifetime history of treatment resistant depression, defined as having not responded to adequate treatment with 2 or more treatment regimens.
- •Subject has a current co-morbid psychiatric disorder that is either controlled with medications prohibited in this study or is uncontrolled and associated with significant symptoms.
- •Subject has been hospitalized (within the last 12 months) for their current MDD episode.
- •Subject has a current or lifetime history of attention-deficit/hyperactivity disorder (ADHD).
- •Subject has a first degree relative that has been diagnosed with bipolar I disorder.
- •Subject has a recent history (within the last 6 months) of suspected substance abuse or dependence disorder.
- •Subject is considered a suicide risk, has previously made a suicide attempt within the past 3 years, or is currently demonstrating active suicidal ideation.
- •Subject has a concurrent chronic or acute illness or unstable medical condition.
- •Subject has a history of seizures (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder, serious neurological disease, history of significant head trauma, dementia, cerebrovascular disease, Parkinson's disease, or intracranial lesions.
- •Subject has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems.
- •Subject has a history of thyroid disorder that has not been stabilized on thyroid medication or treatment within 3 months prior to the Screening Visit.
- •Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
- •Subject has glaucoma.
- •Subject has any clinically significant ECG or clinical laboratory abnormalities.
- •Subject has a history of moderate to severe hypertension.
- •Current use of any other medications (including over-the-counter [OTC], herbal or homeopathic preparations) that have central nervous system effects.
- •Subject has the potential need to initiate or modify frequency of psychotherapy or to continue or initiate other treatments for depression, outside of those allowed in this protocol.
- •Subject has had electroconvulsive therapy (ECT) for the current depressive episode 3 months prior to the Lead-in Baseline Visit.
- •The subject has a known or suspected intolerance or hypersensitivity to the investigational product.
- •The subject has a known or suspected intolerance, hypersensitivity, or contraindications to their assigned antidepressant treatments (escitalopram oxalate, sertraline HCl, venlafaxine HCl extended release, or duloxetine HCl).
- •Subject has a positive urine drug result.
- •Subject has a body mass index (BMI) of <18.5 or >
- •Subject is female and is pregnant or nursing.
研究组 & 干预措施
Antidepressant + SPD489
Experimental
干预措施: Antidepressant + SPD489 (Lisdexamfetamine dimesylate ) (Drug)
Antidepressant + Placebo
Placebo Comparator
干预措施: Antidepressant + Placebo (Drug)
结局指标
主要结局
Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 8 Weeks
时间窗: 8 weeks
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.
次要结局
- Percentage of Participants Achieving a 50% Response on the MADRS(Up to 8 weeks)
- Mean Change From Baseline in Sheehan Disability Scale (SDS) Total Score at 8 Weeks(8 weeks)
- Percentage of Participants Achieving a 25% Response on the MADRS(Up to 8 weeks)
- Percent of Participants Achieving Remission on the MADRS(Up to 8 weeks)
- Mean Change From Baseline Over Time in MADRS Total Score(Up to 8 weeks)
- Mean Change From Baseline in Abbreviated Brief Assessment of Cognition Affective Disorders (ABAC-A) Composite T-Scores(up to 8 weeks)
- Mean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2)(Up to 8 weeks)
- Mean Change in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score Male(Up to 8 weeks)
- Mean Change in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score Female(Up to 8 weeks)
- Clinical Global Impressions - Global Improvement (CGI-I)(Up to 8 weeks)
- Mean Change From Baseline in the Multidimensional Assessment of Fatigue (MAF) Global Fatigue Index (GFI)(Up to 8 weeks)
- Columbia Suicide Severity Rating Scale (C-SSRS)(Up to 8 weeks)
- Amphetamine Cessation Symptom Assessment (ACSA) - Total Aggregate Score(8 weeks)
研究者
研究点 (101)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderMajor Depressive DisorderNCT01436149Shire1,262
已完成
2 期
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderMajor Depressive DisorderNCT01435759Shire1,197
终止
3 期
SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension StudyMajor Depressive DisorderNCT01436175Shire1,570
终止
1 期
Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression?DepressionNCT02049385National Institute of Mental Health (NIMH)10
已完成
2 期
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive MedicineDepressive Disorder, MajorNCT06280235Boehringer Ingelheim84